Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression

Overview of attention for article published in Frontiers in oncology, March 2023

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 3 Mendeley

So far, Altmetric has seen 1 X post from an account with 6,531 followers.

New research: Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression: Background Atezolizumab may provide clinical benefits to… https://t.

21 Mar 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.